Universitat Autònoma de Barcelona-ko ikertzaileekin lankidetzan egindako argitalpenak (21)

2023

  1. Cutibacterium spp. Infections after Instrumented Spine Surgery Have a Good Prognosis Regardless of Rifampin Use: A Cross-Sectional Study

    Antibiotics, Vol. 12, Núm. 3

  2. Vertebral osteomyelitis after spine instrumentation surgery: risk factors and management

    Journal of Hospital Infection, Vol. 140, pp. 102-109

2021

  1. Implant removal in the management of prosthetic joint infection by staphylococcus aureus: Outcome and predictors of failure in a large retrospective multicenter study

    Antibiotics, Vol. 10, Núm. 2, pp. 1-13

  2. Prosthetic shoulder joint infection by Cutibacterium acnes: Does rifampin improve prognosis? A retrospective, multicenter, observational study

    Antibiotics, Vol. 10, Núm. 5

2019

  1. Week 96 efficacy and safety results of the phase 3, randomized EMERALD trial to evaluate switching from boosted-protease inhibitors plus emtricitabine/tenofovir disoproxil fumarate regimens to the once daily, single-tablet regimen of darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in treatment-experienced, virologically-suppressed adults living with HIV-1

    Antiviral Research, Vol. 170

2018

  1. Factors leading to the loss of natural elite control of HIV-1 infection

    Journal of Virology, Vol. 92, Núm. 5

  2. Mitochondrial haplogroup H is related to CD4+ T cell recovery in HIV infected patients starting combination antiretroviral therapy

    Journal of Translational Medicine, Vol. 16, Núm. 1

2016

  1. Short- versus long-duration levofloxacin plus rifampicin for acute staphylococcal prosthetic joint infection managed with implant retention: a randomised clinical trial

    International Journal of Antimicrobial Agents, Vol. 48, Núm. 3, pp. 310-316

2015

  1. Primary resistance to integrase strand-transfer inhibitors in Europe

    Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 10, pp. 2885-2888

  2. Virological failure to raltegravir in Spain: Incidence, prevalence and clinical consequences

    Journal of Antimicrobial Chemotherapy, Vol. 70, Núm. 11, pp. 3087-3095

2014

  1. Abacavir/lamivudine plus darunavir/ritonavir in routine clinical practice: A multicentre experience in antiretroviral therapy-naive and -experienced patients

    Journal of Antimicrobial Chemotherapy, Vol. 69, Núm. 9

  2. Executive summary of the recommendations on the evaluation and management of renal disease in human immunodeficiency virus-infected patients

    Enfermedades Infecciosas y Microbiologia Clinica, Vol. 32, Núm. 9, pp. 583-597

  3. Gram-negative prosthetic joint infection: Outcome of a debridement, antibiotics and implant retention approach. A large multicentre study

    Clinical Microbiology and Infection, Vol. 20, Núm. 11, pp. O911-O919

  4. Opportunistic infections and AIDS malignancies early after initiating combination antiretroviral therapy in high-income countries

    AIDS, Vol. 28, Núm. 16, pp. 2461-2473

  5. Resumen ejecutivo del documento de consenso sobre el manejo de la patología renal en pacientes con infección por VIH

    Nefrologia, Vol. 34, Núm. 6, pp. 768-788

2013

  1. A large multicenter study of methicillin-susceptible and methicillin-resistant staphylococcus aureus prosthetic joint infections managed with implant retention

    Clinical Infectious Diseases, Vol. 56, Núm. 2, pp. 182-194

2012

  1. Clinical, virological and biochemical evidence supporting the association of HIV-1 reverse transcriptase polymorphism R284K and thymidine analogue resistance mutations M41L, L210W and T215Y in patients failing tenofovir/emtricitabine therapy

    Retrovirology, Vol. 9

  2. Mutations in the protease gene associated with virological failure to lopinavir/ritonavir-containing regimens

    Journal of Antimicrobial Chemotherapy, Vol. 67, Núm. 6, pp. 1462-1469

2010

  1. Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per μl in Europe and North America: A pooled cohort observational study

    The Lancet, Vol. 376, Núm. 9738, pp. 340-345

  2. The future of antiretroviral therapy: Challenges and needs

    Journal of Antimicrobial Chemotherapy, Vol. 65, Núm. 5, pp. 827-835